You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

18 search results for: real-world data

expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

18 min

Dermatology

The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

22 min

Dermatology

The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

expert video

Role of Type 2 Inflammation in Chronic Inflammatory Diseases

15 min

Dermatology

Type 2 inflammatory mechanisms and key type 2 cytokines in the pathogenesis of atopic dermatitis – Presentation from the ADVENT symposium at ISID 2023

expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

69 min

Dermatology

Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.

expert video

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

43 min

Dermatology

This video presentation of the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga, Dr. Amy Paller, and Prof. Lisa Weibel. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating children with AD early in the disease course, and the emerging clinical and real-world data on the use of advanced systemic treatments for children with AD.

expert video

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

45 min

Dermatology

This video presentation of the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands features Dr. Stephan Weidinger, Dr. Eric Simpson, and Dr. Marjolein de Bruin-Weller. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating patients with AD early in the disease course, and the emerging real-world data on the use of advanced systemic therapies for patients with AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SudanChange country/region